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Abstract
Mitochondrial dysfunction is a hallmark of beta-amyloid (Ab)-induced neurotoxicity in Alzheimer’s disease (AD), and is
considered an early event in AD pathology. Diammonium glycyrrhizinate (DG), the salt form of Glycyrrhizin, is known for its
anti-inflammatory effects, resistance to biologic oxidation and membranous protection. In the present study, the
neuroprotective effects of DG on Ab1–42-induced toxicity and its potential mechanisms in primary cortical neurons were
investigated. Exposure of neurons to 2 mMA b1–42 resulted in significant viability loss and cell apoptosis. Accumulation of
reactive oxygen species (ROS), decreased mitochondrial membrane potential, and activation of caspase-9 and caspase-3
were also observed after Ab1–42 exposure. All these effects induced by Ab1–42 were markedly reversed by DG treatment. In
addition, DG could alleviate lipid peroxidation and partially restore the mitochondrial function in Ab1–42-induced AD mice.
DG also significantly increased the PGC-1a expression in vivo and in vitro, while knocking down PGC-1a partially blocked the
protective effects, which indicated that PGC-1a contributed to the neuroprotective effects of DG. Furthermore, DG
significantly decreased the escape latency and search distance and increased the target crossing times of Ab1–42-induced
AD mice in the Morris water maze test. Therefore, these results demonstrated that DG could attenuate Ab1–42-induced
neuronal injury by preventing mitochondrial dysfunction and oxidative stress and improved cognitive impairment in Ab1–42-
induced AD mice, indicating that DG exerted potential beneficial effects on AD.
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Introduction
Alzheimer’s disease (AD), with typical pathological abnormal-
ities including amyloid plaques, neurofibrillary tangles and neuron
death, is the most prevalent neurodegenerative disease [1]. Beta-
Amyloid (Ab) is the primary component of senile plaques and Ab-
induced oxidative stress and neuronal apoptosis play an important
role in the pathogenesis of AD [2,3,4]. Persuasive evidence
indicates that Ab leads to the mitochondrial dysfunction partially
by causing an imbalance of mitochondrial fission/fusion and
impairing the mitochondrial biogenesis [5,6,7]. Moreover, Ab was
demonstrated to interact with Ab-binding alcohol dehydrogenase
(ABAD), which caused the release of reactive oxygen species
(ROS), diminished cytochrome c activity and ATP depletion in
AD patients and transgenic mice [8,9,10]. Thus, one promising
preventive or therapeutic strategy for treatment of AD may be to
attenuate or suppress Ab-mediated oxidative stress and mitochon-
drial dysfunction.
The peroxisome proliferator-activated receptor gamma coacti-
vator 1 (PGC-1) are a small family of transcriptional coactivators
which play a critical role in the control of glucose, lipid, and
energy metabolism [11]. There are three known isoforms of PGC-
1: PGC-1a, PGC-1b and PGC-1-related coactivator. The
physiological significance of PGC-1 in mitochondrial energy
metabolism has been well demonstrated [12,13]. Several groups
including our studies have demonstrated that PGC-1a exerted
neuroprotective effects in multiple neurological diseases
[14,15,16,17]. An intriguing finding in these studies was that
PGC-1a null mice developed spongiform neurodegeneration in
selective brain areas, which indicated the direct role of PGC-1a in
the neurodegeneration [13]. PGC-1a was a direct target of cyclic
AMP (cAMP) response element binding (CREB) in vivo and
CREB-dependent gene expression played critical roles in the
neuroplasticity associated with cognitive function [18].
Glycyrrhizin (GL), which is extracted in liquorice root, has a
wide range of pharmacological actions including anti-virus, anti-
allergenic and anti-immune-mediated cytotoxicity [19,20,21,22].
Diammonium glycyrrhizinate (DG), which is also extracted and
purified from liquorices, is more stable, soluble and has more
significant bioactivities than GL. DG has been used for treatment
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inflammatory effect, resistance to biologic oxidation and mem-
branous protection [23,24]. This study demonstrated that DG
suppressed Ab1–42-induced oxidative stress and mitochondrial
dysfunction partially via induction of PGC-1a and alleviated Ab1–
42-induced cognitive impairment, suggesting DG might be
developed into a promising drug for treatment of AD.
Materials and Methods
Ab1–42 induced AD mice model
The Ab1–42 (Millipore, CA, USA) was dissolved in 1%
NH3?H2O at a concentration of 1 mg/ml and incubated at 37uC
for 5 days to allow for fibril formation. DG was purchased from
Jiangsu Chia-Tai Tianqing Pharmacy Company. The male ICR
mice (weight range: 15–20 g) were anesthetized and Ab1–42 (4 mg,
i.c.v) was injected to bilateral hippocampus by infusion cannulae.
DG was co-injected intraperitoneally with Ab1–42. The mice were
randomly assigned into four groups: the normal mice with saline
or DG (10 mg/kg/day, i.p. for 14 days), and Ab1–42-induced AD
mice with saline or DG (10 mg/kg/day, i.p. for 14 days). All
animal experiments were approved by the Animal Care
Committee in Nanjing University and performed according to
institutional guidelines. We made every effort to minimize the
number of mice used and their suffering.
Cell culture and treatment
Primary cortical neurons were prepared from E15–17 mouse
embryo. Cortexes were dissected and plated at 4610
5 cells/ml on
poly-D-lysine-coated plates. Cells were maintained in Neurobasal
media supplemented with B27 (Invitrogen, Carlsbad, California,
USA) and 25 nM glutamine at 37uC in a humidified 5% CO2
incubator. The purity of neurons was over 95%. The cells at day 8
were incubated with 2 mMA b1–42 with DG or saline for 24 h.
HEK293T, BV-2 and RAW264.7 cells were obtained from
American Type Culture Collection (ATCC) and maintained in
DMEM containing 10% of heat-inactivated fetal bovine serum
(FBS), 2 mmol/L of L-glutamine, 100 U/ml of penicillin, and
100 mg/ml of streptomycin at 37uC in a humidified 5% CO2
incubator.
Plasmid construct and transient transfection
Small hairpin RNAs (shRNAs) were synthesized and subse-
quently cloned into pCMV-U6 vector using Bbsl and BglII
(Fermentas Inc., USA). Five PGC-1a shRNAs sequences (shP1–
shP5) were designed to target mouse PGC-1a gene. The plasmid
expressing scrambled shRNA (sh-con) was used as a negative
control. ShRNA sequences were as follows:
shP1: Forward: 59-TTTGGCCATTGTTAAGACCGAGAA-
TCTCGAGATTCTCGGTCTTAACAATGGCTTTTTG-39,
Reverse: 59-GATCCAAAAAGCCATTGTTAAGACCGAGA-
ATCTCGAGATTCTCGGTCTTAACAATGGC-39;
shP2: Forward: 59-TTTGCCCATTTGAGAACAAGACTAT-
CTCGAGATAGTCTTGTTCTCAAATGGGTTTTTG-39,
Reverse: 59-GATCCAAAAACCCATTTGAGAACAAGACTA-
TCTCGAGATAGTCTTGTTCTCAAATGGG-39;
shP3: Forward: 59-TTTGCGGAGACTATTGAGCGAACC-
TTAACTCGAGTTAAGGTTCGCTCAATAGTCTTTTTTT-
G-39, Reverse: 59-GATCCAAAAAAAGACTATTGAGCGAAC-
CTTAACTCGAGTTAAGGTTCGCTCAATAGTCTCCG-39;
shP4: Forward: 59-TTTGCGGTAACTATGCAGACCTAGA-
TACCTCGAGGTATCTAGGTCTGCATAGTTATTTTTT-
G-39, Reverse: 59-GATCCAAAAAATAACTATGCAGACCTA-
GATACCTCGAGGTATCTAGGTCTGCATAGTTACCG-39;
shP5: Forward: 59-TTTGTCCAGTAAGCACACGTTTATT-
CTCGAGAATAAACGTGTGCTTACTGGATTTTTG-39, Re-
verse: 59-GATCCAAAAATCCAGTAAGCACACGTTTATTC-
TCGAGAATAAACGTGTGCTTACTGGA-39.
sh-con: Forward: 59-TTTGGCATTGCTTCTGTGTAAAT-
TACTCGAGTAATTTACACAGAAGCAATGCTTTTTG-39,
Reverse: 59-GATCCAAAAAGCATTGCTTCTGTGTAAAT-
TACTCGAGTAATTTACACAGAAGCAATGC-39.
The oligonucleotides were synthesized by Biocolor BioScience
and Technology Company (Invitrogen, USA). shRNAs were
transfected into neurons using Lipofectamine 2000 (Invitrogen,
CA, USA) according to the manufacturer’s instructions. Cells were
harvested for RT-PCR and western blotting at 24 h after the
transfection.
Apoptotic assay by flow cytometry
Apoptosis was determined by Annexin V-FITC apoptosis
detection kit (KeyGen Biotech, Nanjing, China). After treatment,
the cells were rinsed with PBS twice, centrifuged at 600 g for
10 min and resuspended in 0.5 ml binding buffer containing 5 ml
Annexin V and 5 ml propidium iodide (PI), and then incubated for
15 min at 37uC in the dark. The apoptotic rate was examined by
flow cytometry.
MTT assay
Cell viability was determined using the conventional MTT
assay. After treatment, primary cortical neurons were treated with
0.5 mg/ml MTT for 4 h at 37uC. The formazan crystals were
dissolved in 100 ml of DMSO and the absorbance was measured
at 570 nm in a plate reader. Cell survival rates were expressed as
percentages of the value of normal cells.
LDH assay
LDH is the most widely used marker in cytotoxicity study. At
the end of incubation, the supernatant was collected from plates
and the LDH content was determined using an LDH assay kit
according to the manufacturer’s instructions (Nanjing Institute of
Jianchen Biological Engineering, China). LDH cytotoxicity was
calculated by the following formula: LDH cytotoxicity=(sample
OD2blank OD)/(standard solution OD2blank standard solution
OD )62000.
Measurement of mitochondrial membrane potential
Change of the mitochondrial transmembrane potential in
neurons was quantified by JC-1 (Beyotime, Nanjing, China).
Briefly, neuronal cells were centrifuged at 600 g for 10 min, and
resuspended in 0.5 ml medium containing 5 mM JC-1. After
20 min of incubation at 37uC in the dark, the cells were washed
with PBS twice and resuspended in 0.5 ml PBS. Samples were
analyzed by flow cytometry.
Measurement of intracellular ROS
To monitor intracellular accumulation of ROS, flow cytometry
was used with commercial kit (Beyotime, Nanjing, China)
according to the manufacturer’s instructions. After treatment,
the cells were harvested, rinsed with PBS twice, centrifuged at
600 g for 10 min, and then resuspended in 10 mM DCFH-DA
solutions. After 20 min of incubation at 37uC, cells were washed
with PBS twice and resuspended in 0.5 ml PBS. Samples were
analyzed by flow cytometry.
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The levels of 4-HNE from hippocampus and serum were
measured by the ELISA kits (Genmed Scientifics Inc, USA)
according to the manufacturer’s instruction. Briefly, supernatant
from hippocampus or serum were added into the 96-well plate
coated with purified anti-4-HNE antibody, and then HRP-labeled
4-HNE antibody was added. The absorbance was measured at
450 nm and the concentration of 4-HNE was determined by
comparing the O.D. of the sample to the standard curve.
Cytochrome c detection
For measurement of cytochrome c release, the mitochondrial
and cytosol fractions were prepared according to the manufac-
turer’s instructions (Beyotime, Nanjing, China). Briefly, mice
hippocampus were washed twice with cold PBS, resuspended in
fresh cytosolic extract buffer and incubated for 30 min on ice with
frequent tube tapping. Tissues were homogenized on ice, and then
nuclei, unbroken cells, and cell debris were pelleted at 600 g for
10 min at 4uC. The supernatant was spun again at 13,000 g for
20 min at 4uC. The supernatant was carefully transferred and the
final pellet was used as the mitochondrial fraction. The
cytochrome c levels were determined using a monoclonal antibody
to cytochrome c by western blotting as described below.
Western blotting
Equal amounts of protein were separated by SDS-PAGE and
electrophoretically transferred onto polyvinylidene fluoride mem-
branes. Membranes were blocked with 5% non-fat dry milk for
1 h and incubated overnight at 4uC with rabbit anti-cleaved
caspase-3 (1: 500, Bioworlde), rabbit anti-caspase-3 (1: 500,
Bioworlde), rabbit anti-caspase-9 (1: 1,000, Cell signaling), rabbit
anti-PGC-1a (1: 1000, Millipore), mouse anti-cytochrome c (1:
500, Abcam), or mouse anti-GAPDH (1: 5000, Bioworlde)
antibody. GAPDH was used as a loading control. The proteins
were detected with horseradish peroxidase-conjugated anti-rabbit
or anti-mouse secondary antibodies and visualized with chemilu-
minescence reagents provided with the ECL kit (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) and exposure to film.
The intensity of the blots was quantified with densitometry.
Caspase-9 and -3 activity assay
Caspase-3 and caspase-9 activities of primary cortical neurons
were measured by means of colorimetric assay kits (Keygen
BioTech, Nanjing, China), according to the manufacturer’s
instructions. In brief, harvested cells were incubated with 50 ml
lysis buffer on ice for 30 min, followed by centrifugation at
10,000 g for 1 min at 4uC. Then, cells were suspended in 50 ml
26reaction buffer and 5 ml caspase-3 or caspase-9 substrate
incubating for 4 h at 37uC. Later, the absorbance was read in a
microplate reader at 400 nm.
Real-time PCR and RT-PCR
Real-time PCR was performed as described previously [14].
Total RNA was extracted by using the Trizol reagent (Takara,
Dalian, China) and was reverse-transcribed into cDNA using a
PrimeScript RT reagent kit (Takara, Dalian, China) for Quanti-
tative PCR (ABI 7500, USA) in the presence of a fluorescent dye
(SYBR Green I; Takara). The relative abundance of mRNA was
calculated after normalization to GAPDH mRNA. The primers
are as follows:
PGC-1a: Forward: 59-TGACACAACGCGGACAGAA-39, Re-
verse: 59-GGTAGGTGATGAAACCATAG-39;
GAPDH: Forward: 59-GCCAAGGCTGTGGGCAAGGT-39,
Reverse: 59-TCTCCAGGCGGCACGTCAGA-39.
The PCR products were analyzed on 1.5% agarose gels and
visualized by ethidium bromide. The gel was visualized with UV-
transilluminator and photographed.
Luciferase reporter activity assays
The promoter regions of mouse PGC-1a (23000 to 0 bp) were
amplified using PCR, DNAs of primary cortical neurons as
templates, and specific primers with MluI and BglII restriction
enzyme (Fermentas Inc., USA) cut sites engineered on the ends
(Forward: 59-ATAAACGCGTAATGTGTGGCCGAACACAC-
TGT-39, Reverse: 59-CGCCGAGATCTAAAGCTATTAAAAA-
GTAGGCT-39) to facilitate directional cloning. The PCR
products were cloned into the pGL3 basic in sense orientation
(designated as p-PGC-3K). The truncated constructs were made
using the following primers:
23000–2500 bp (named as p-PGC-0.5K): Forward: 59-AT-
AAACGCGTAATGTGTGGCCGAACAC-39, Reverse: 59-GT-
CGAGATCTCTTGTGTTTCTGCTGCTA-39;
23000–2000 bp (named as p-PGC-1K): Forward: 59-AT-
AAACGCGTAATGTGTGGCCGAACAC-39, Reverse: 59-GT-
CGAGATCTTCTACTTTCCACACAGTC-39;
23000–1500 bp (named as p-PGC-1.5K): Forward: 59-AT-
AAACGCGTAATGTGTGGCCGAACAC-39, Reverse: 59-CC-
GCCGAGATCTTCTGACTTTATATAGTC-39;
23000–1000 bp (named as p-PGC-2K): Forward: 59-AT-
AAACGCGTAATGTGTGGCCGAACACACT-39, Reverse: 59-
GCCGAGATCTTCCAACCCTAGTGCCTTG-39;
23000–500 bp (named as p-PGC-2.5K): Forward: 59-AT-
AAACGCGTAATGTGTGGCCGAACACACT-39, Reverse: 59-
GCCGAGATCTGATTTTCTTTCTCTCTCTCCT-39;
2500–0 bp (named as p-PGC-500 bp): Forward: 59-AAA-
TAAACGCGTGGGGGTGTTGCCTTCAAAC-39, Reverse: 59-
GCCCCGAGATCTAAAGCTATTAAAAAGTAGG-39.
The sequence of 2100–0 bp in the PGC-1a promoter (named
as p-PGC-100 bp), CREB binding site mutation sequence (named
as p-PGC-100 bp mutate) and deletion sequence (named as p-
PGC-100 bp delete) were synthesized with MluI and BglII
restriction enzyme cut sites as followers:
p-PGC-100 bp: Forward: 59-CGCGTGAGGGCTGCCTTG-
GAGTGACGTCAGGAGTTTGTGCAGCAAGCTTGCACA-
GGAGAAGGGAGGCTGGGTGAGTGACAGCCCAGCCTA-
CTTTTTAATAGCTTTA-39, Reverse: 59GATCTAAAGCTA-
TTAAAAAGTAGGCTGGGCTGTCACTCACCCAGCCTC-
CCTTCTCCTGTGCAAGCTTGCTGCACAAACTCCTGA-
CGTCACTCCAAGGCAGCCCTCA-39;
p-PGC-100 bp mutate: Forward: 59-CGCGTGAGGGCT-
GCCTTGGAGTGTGGTCAGGAGTTTGTGCAGCAAGCT-
TGCACAGGAGAAGGGAGGCTGGGTGAGTGACAGCCC-
AGCCTACTTTTTAATAGCTTTA-39, Reverse: 59-GATC-
TAAAGCTATTAAAAAGTAGGCTGGGCTGTCACTCACC-
CAGCCTCCCTTCTCCTGTGCAAGCTTGCTGCAC-
AAACTCCTGACCACACTCCAAGGCAGCCCTCA-39;
p-PGC-100 bp delete: Forward: 59-CGCGTGAGGGCTG-
CCTTGGAGGGAGTTTGTGCAGCAAGCTTGCACAGGA-
GAAGGGAGGCTGGGTGAGTGACAGCCCAGCC-
TACTTTTTAATAGCTTTA-39, Reverse: 59-GATCTAAAGC-
TATTAAAAAGTAGGCTGGGCTGTCACTCACC-
CAGCCTCCCTTCTCCTGTGCAAGCTTGCTGCA-
CAAACTCCCTCCAAGGCAGCCCTCA-39.
All transfection experiments in this study were performed with
Lipofectamine 2000 (Invitrogen) following the manufacturer’s
instructions. pPGCs and phRL-CMV Renilla were cotransfected to
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was assayed by using the Promega Bright-N-Glo system as
previously described [25]. All data points were the averages of at
least four independent transfections.
Morris water maze test
The Morris water maze test was conducted as previously
described [26]. Briefly, mice were trained to find a transparent
Plexiglas platform in the pool placed 2 cm below the water surface
in the middle of one quadrant. The position of the platform was
unchanged during the training trials. Four time training trails per
day were conducted for four consecutive days from 14 days after the
injection. In each trial, the latency to escape on the platform was
recorded for 1 min. Data of each mice behavior were collected by a
video camera linked to a computer through an image analyzer. The
total sum of latency and searching distance for the platform in four
trials of each mouse was counted for all tested mice per group per
day. At the end of the training period, mice were tested on a spatial
probe trial in which the platform was removed from the pool, and
each mouse was allowed to swim freely for 1 min. During the probe
trial, the number of platform crossings was recorded. The recorded
data were used to analyze mice performance.
Statistical analysis
The data were expressed as means 6 SEM and analyzed by
SPSS12.0 statistical analytical software (SPSS, Chicago, IL, USA).
Group differences in the escape latency, searching distance and
swimming speed during the Morris water maze test were analyzed
using two-way analysis of variance (ANOVA) with repeated
measures followed by Bonferroni post hoc test with day and
treatment as the sources of variation. Otherwise comparison
between two groups was statistically evaluated by Student’s t-test
and multiple group comparisons were analyzed by one-way
ANOVA followed by Tukey post hoc test. Values of P,0.05 were
considered statistically significant.
Figure 1. Protective effects of DG on Ab1–42-induced cytotoxicity in primary cortical neurons. (A) Neurons were incubated with 2 mM
Ab1–42 and different concentrations of DG for 24 h, and the cell viability was estimated by the MTT assay. (B) Assessment of apoptosis in neurons
incubated with 2 mMA b1–42 and 0.001 mg/ml DG for 24 h by Annexin V/PI double-staining. (C) Quantitative analysis of apoptotic cells. (D) LDH assay
of neurons incubated with 2 mMA b1–42 and 0.001 mg/ml DG for 24 h. All data shown represent the mean6 SEM of at least three independent
experiments. ** P,0.01 for one-way ANOVA followed by Tukey post hoc test compared with control; # P,0.05 and ## P,0.01 for one-way ANOVA
followed by Tukey post hoc test compared with Ab1–42-treated, respectively.
doi:10.1371/journal.pone.0035823.g001
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DG protects neurons from Ab1–42-induced neurotoxicity
in vitro
To investigate whether DG could suppress the cellular toxicity
induced by Ab, the primary cortical neurons were incubated with
Ab1–42 (2 mM) and different concentrations of DG or saline. As
expected, the viability of cortical neurons exposed to Ab1–42 was
reduced by 34.1% in comparison with the control group (P,0.01,
Figure 1A) and DG significantly enhanced neuron viability
(P,0.05, Figure 1A).
To further confirm the neuroprotection of DG on Ab1–42-
mediated toxicity, neuronal apoptosis was detected by Annexin V
and PI staining. As shown in Figure 1B and 1C, cell apoptosis was
demonstrated in Ab1–42-treated neurons compared with the
control, while significantly attenuated after treatment of DG. In
addition, the inhibition of Ab1–42-induced neuronal death in
presence of DG was confirmed by the LDH assay (Figure 1D).
DG decreases the oxidative damage induced by Ab1–42
Emerging evidence suggests that mitochondrial dysfunction and
oxidative stress are involved in Ab1–42-induced neurotoxicity.
Thus, this study surmised that DG might be able to reduce Ab1–42-
mediated mitochondrial dysfunction and excessive production of
ROS which was mainly produced by mitochondria. As shown in
Figure 2A and 2B, exposure of cortical neurons to Ab1–42 led to an
increase in ROS production; whereas the effect was significantly
decreased by treatment with DG (1365.67667.52 vs.
705.67651.87, P,0.01). To further investigate DG’s ability to
inhibit Ab-induced oxidative stress, a marker of lipid peroxidation,
4-HNE was examined. As shown in Figure 2C and 2D, 4-HNE
levels in the serum and hippocampus of Ab1–42-induced AD mice
were significantly increased by 40.4% and 67.3% compared to
control mice respectively (P,0.05), while 4-HNE levels were
reduced 24.2% and 33.2% in the serum and hippocampus after
DG treatment respectively (P,0.05).
DG prevents mitochondrial dysfunction mediated by
Ab1–42
Mitochondrial membrane potential (Dy) is widely recognized as
an indicator of mitochondrial functionality, which is measured by
JC-1, a cationic lipophilic fluorescent. The results showed that
there was a significant loss of Dy in neurons treated with Ab1–42
(Figure 3A and 3B, P,0.01). However, the decrease of Dy
induced by Ab1–42 was greatly alleviated after DG treatment
(Figure 3A and 3B, P,0.01), indicating that DG protected
mitochondrial against Ab1–42-induced injury. Meanwhile, the
activities of caspase -9 and caspase-3, were assessed. As shown in
Figure 3C and 3D, the activities of caspase-9 and caspase-3 were
significantly increased by 44.80% and 68.17% of the control group
in Ab1–42-treated neurons, while DG-treated neurons exhibited
lower caspase-9 and caspase-3 activities compared to Ab1–42-
treated neurons (P,0.05).
Figure 2. DG treatment decreased the oxidative stress induced by Ab1–42. (A) Neuronal cells were treated with 2 mMA b1–42 and 0.001 mg/ml
DG for 24 h and intracellular ROS was determined by flow cytometry. (B) Quantitative analysis of ROS. (C) The concentration of 4-HNE in the serum of
normal and Ab1–42-treated AD mice with saline or DG were determined by ELISA. (D) The concentration of 4-HNE in the hippocampus of normal mice
with saline or DG, and Ab1–42-induced AD mice with saline or DG were determined by ELISA. Results were shown as the mean6 SEM and represented
at least three independent experiments. * P,0.05 and ** P,0.01 for one-way ANOVA followed by Tukey post hoc test compared with control,
respectively; # P,0.05 and ## P,0.01 for one-way ANOVA followed by Tukey post hoc test compared with Ab1–42-treated, respectively. n=5 mice
per group.
doi:10.1371/journal.pone.0035823.g002
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dysfunction induced by Ab in vivo, the release of cytochrome c
from the mitochondrial membrane as well as the subsequent
activation of caspase-9 and caspase-3 was investigated by western
blotting. The levels of cytosolic cytochrome c expression in Ab1–42-
induced AD mice were significantly increased, which were
significantly reversed by the treatment with DG (Figure 3E and
3F). In addition, DG could inhibit the activation of caspase-9 and
caspase-3 in Ab1–42-induced AD mice (Figure 3E and 3F).
PGC-1a may be involved in DG -afforded
neuroprotection against Ab1–42
Next, whether the neuroprotection of DG against Ab1–42-
induced neurotoxicity was related to the expression of PGC-1a in
neurons was addressed. The results indicated that DG markedly
increased the mRNA expression of PGC-1a at 3 h (1.1460.05-
fold), 6 h (1.4760.08-fold), 12 h (1.7060.11-fold), 24 h
(2.1160.48-fold) and 48 h (1.2460.38-fold) (Figure 4A), with
similar protein expression pattern (Figure 4B and 4C). PGC-1a
was also down-regulated in Ab1–42-induced AD mice, while DG
Figure 3. DG treatment rescued the mitochondrial dysfunction induced by Ab1–42. (A) Neuronal cells were treated with 2 mMA b1–42 and
0.001 mg/ml DG for 24 h and mitochondrial membrane potential was measured by flow cytometry using JC-1. (B) Quantitative analysis of
mitochondrial membrane potential. Neuronal cells were treated with 2 mMA b1–42 and 0.001 mg/ml DG for 24 h and Caspase-9 (C) and caspase-3 (D)
activities were measured by means of colorimetric assay kits. (E) The expression of cytosolic, mitochondrial cytochrome c, caspase-9 and caspase-3 of
hippocampus of normal mice with saline or DG, and Ab1–42-induced AD mice with saline or DG was determined by western blotting. (F) Quantitative
analysis of the relative protein levels of Figure 3E. Results were shown as the mean6 SEM and represented at least three independent experiments.
* P,0.05 and ** P,0.01 for one-way ANOVA followed by Tukey post hoc test compared with control, respectively; # P,0.05 and ## P,0.01 for one-
way ANOVA followed by Tukey post hoc test compared with Ab1–42-treated, respectively. n=4 mice per group.
doi:10.1371/journal.pone.0035823.g003
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and 4E). To demonstrate whether PGC-1a contributed to the
neuroprotection of DG, endogenous PGC-1a was knocked down
by shRNAs (Figure 5A to 5D) and the results of MTT revealed
that PGC1a-shRNA could partially block neuroprotective effects
by DG in Ab1–42-treated neurons (Figure 5E).
To explore whether DG could induce the transcriptional activity
of PGC-1a, p-PGC-3K and five truncated plasmids were
constructed. As shown in Figure 6A, DG treatment significantly
up-regulated thetranscriptional activityof PGC-1a by 6.23-foldat a
concentration of 0.001 mg/ml, and 5.13-fold at a concentration of
0.005 mg/ml in neurons (P,0.01). Also DG treatment significantly
up-regulated the transcriptional activity of PGC-1a by 4.08-fold in
HEK293T cells,1.98-fold inBV-2cells and1.62-fold inRAW264.7
cells at a concentration of 0.001 mg/ml, indicating that induction of
transcriptional activity of PGC-1a by DG may not be cell type
specific (Figure 6B). Interestingly, DG significantly downregulated
the transcriptional activity of p-PGC-2.5K while increasing the
transcriptionalactivityofp-PGC-3K(P,0.01),whichindicatedthat
2500–0 bp in the promoter of PGC-1a might be involved in the
protective effects of DG (Figure 6C). To explore whether the CREB
binding sequence (284–77 bp) was essential for the DG-induced
transcriptional activity of PGC-1a, 2100–0 bp of the PGC-1a
promoter and the CREB binding sites mutated/deleted sequences
were constructed. As shown in Figure 6D, mutation or deletion of
the CREB binding sequence completely abolished the induction of
the transcriptional activity of PGC-1a, which suggested that CREB
might play an important role in the DG-induced transcriptional
activity of PGC-1a.
DG improves cognitive impairment in Ab1–42-induced AD
mice
To explore whether DG could improve cognitive impairment in
Ab1–42-induced AD mice, Morris water maze test was employed.
Escape latency reflects the ability of learning and remembering the
relationships between multiple distal cues and the platform
location to escape the water, which is a hippocampus-dependent
task. As shown in Figure 7A, DG could decrease the mean latency
reaching to the submerged platform of AD mice (two-way
ANOVA with repeated measures; groups: F(3, 31)=6.123,
P=0.002; days: F(3, 93)=3.620, P=0.016; group x day: F(9,
93)=0.915, P=0.516). In addition, the search distance was also
significantly decreased by DG treatment compared to AD mice
(two-way ANOVA with repeated measures; groups: F(3,
Figure 4. DG treatment significantly increased the expression of PGC-1a in vitro and in vivo. Neurons were treated with 2 mMA b1–42 and
0.001 mg/ml DG for the indicated time points, and the mRNA (A) and protein expression (B) of PGC-1a were analyzed by Real-time PCR and western
blotting respectively. (C) Quantitative analysis of the relative protein levels of PGC-1a. The relative RNA or protein levels of control neurons were
considered 1. Results were shown as the mean6 SEM and represented at least three independent experiments. * P,0.05 and ** P,0.01 for Student’s
t-test compared with Ab1–42-treated, respectively. (D) The expression of PGC-1a of hippocampus of normal mice with saline or DG, and Ab1–42-
induced AD mice with saline or DG was determined by western blotting. (E) Quantitative analysis of the relative protein levels of PGC-1a. Results were
shown as the mean6 SEM and represented at least three independent experiments. ** P,0.01 for one-way ANOVA followed by Tukey post hoc test
compared with control mice; # P,0.05 for one-way ANOVA followed by Tukey post hoc test compared with Ab1–42-treated AD mice. n=4 mice per
group.
doi:10.1371/journal.pone.0035823.g004
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day: F(9, 51)=1.942, P=0.067, Figure 7B). On the fifth day, the
platform was removed and the probe trail was conducted. AD
mice had fewer times crossing the previous platform position than
the normal mice, while those under the treatment of DG
significantly improved their performance (P,0.05, Figure 7C).
No speed differences appeared among these four groups
(Figure 7D). It suggested that DG could alleviate the deficits of
spatial learning and memory in Ab1–42-induced AD mice.
Discussion
In the Ab1–42-induced AD model in vitro and in vivo, this study
for the first time shows: 1) DG exerts neuroprotective effects and
improves cognitive impairment; 2) DG rescues mitochondrial
dysfunction and inhibits oxidative stress; and 3) DG increases the
expression of PGC-1a, which might contribute to the neuropro-
tection of DG.
Mitochondrial dysfunction is a hallmark of Ab1–42-induced
neuronal toxicity, and is considered as an early event in AD
pathology. Several evidences indicated that Ab triggered mito-
chondrial dysfunction through a number of pathways such as
increase of ROS, interaction with ABAD, impaired mitochondrial
biogenesis, and alteration of mitochondrial dynamics [5,6,7,10].
DG is the salt form of glycyrrhizin, a major active constituent
isolated from licorice. Licorice and glycyrrhizin have anti-oxygenic
and anti-inflammatory action in bile acid-induced apoptosis and
necrosis [22] [27,28]. The route of administration of DG was
selected because of good bioavailability reported previously [29],
and our results had shown that DG did not attenuate cognitive
Figure 5. Inhibition of PGC-1a could partially block the neuroprotective effects of DG. Five shRNAs targeted to PGC-1a were constructed
and the efficacy was confirmed by RT-PCR (A) and western blotting (B) in primary cortical neurons. (C) Quantitative analysis of the relative RNA levels
of PGC-1a. (D) Quantitative analysis of the relative protein levels of PGC-1a. (E) Neuronal cells were transfected by shP3 or shP5, 6 h after which cells
were treated with 2 mMA b1–42 and 0.001 mg/ml DG for another 24 h. Cell viability was estimated by the MTT assay. ** P,0.01 for one-way ANOVA
followed by Tukey post hoc test compared with control; # P,0.05 for one-way ANOVA followed by Tukey post hoc test compared with Ab1–42;&
P,0.05 for one-way ANOVA followed by Tukey post hoc test compared with Ab1–42+DG.
doi:10.1371/journal.pone.0035823.g005
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shown). This study indicated that DG could decrease the
accumulation of ROS, rescue the mitochondrial membrane
potential loss and activation of caspase-9 and caspase-3 in Ab1–
42-treated neurons. In addition, DG decreased lipid peroxidation
and release of cytochrome c from the mitochondria, and the
activation of caspase-9 and caspase-3 in Ab1–42-induced AD mice.
Furthermore, this anti-oxidation function of DG could refrain
neurotoxicity mediated by Ab1–42, that is, increased cell viability,
decreased apoptosis and LDH release in Ab1–42-treated neurons.
Regardless of the possible mechanisms of DG restraining
oxidative stress, it is clear that PGC-1a is a major regulator of
mitochondrial biogenesis and is protective against oxidative
damage [30]. In addition, PGC-1, which could bind to and
activate many other transcription factors, played an essential role
in physiological signaling transduction and gene expression [31].
However, the role of PGC-1a in the neurological diseases was not
extensive studied until recently. PGC-1a null mice were much
more sensitive to the neurodegenerative effects of MPTP and
kainic acid, which were oxidative stressors. Increasing PGC-1a
levels dramatically protected neurons from oxidative-stressor-
mediated death [17]. Resveratrol was an ideal compound for
treating neurodegenerative diseases by increased the activity of
numerous proteins, including PGC-1a [32]. Activation or
overexpression of PGC-1a could be used to compensate for
neuronal mitochondrial loss [16]. Expression levels of PGC-1a
were significantly decreased in both AD hippocampus and M17
cells stably expressing human Swedish mutation APP695 [5] .
Consistent with these reports, our data showed that DG increased
the expression of PGC-1a and that knocking down PGC-1a by
shRNAs could block the neuroprotection of DG, suggesting that
PGC-1a contributed to the neuroprotective effect of DG in
Ab1–42-treated neurons.
It is intriguing that DG treatment increased the expression of
PGC-1a in Ab1–42-treated neurons and CREB might play an
important role in induction of the transcriptional activity of PGC-
1a. PGC-1a was a direct target of CREB induction of
gluconeogenesis in vivo [33]. CREB was also essential for long-
Figure 6. DG might induce the transcriptional activity of PGC-1a through CREB. (A) pPGC-3K and phRL-CMV Renilla were cotransfected to
neurons followed by DG treatment at the indicated concentration and the luciferase activity was assayed at 24 h. Results are shown as the mean6
SEM and represent at least four independent experiments. ** P,0.01 for one-way ANOVA followed by Tukey post hoc test compared with control. (B)
pPGC-3K and phRL-CMV Renilla were cotransfected to neurons, HEK293T, BV-2, or RAW264.7 cells followed by DG treatment (0.001 mg/ml) and the
luciferase activity was assayed at 24 h. ** P,0.01 for Student’s t-test compared with pGL-3. (C) pPGCs and phRL-CMV Renilla were cotransfected to
HEK293T cells followed by DG treatment (0.001 mg/ml) and the luciferase activity was assayed at 24 h. (D) pPGC-100 bp or mutated pPGC-100 bp or
deleted pPGC-100 bp were cotransfected to HEK293T cells with phRL-CMV Renilla followed by DG treatment (0.001 mg/ml) and the luciferase activity
was assayed at 24 h. Results are shown as the mean6 SEM and represent at least four independent experiments. * P,0.05 and ** P,0.01 for one-way
ANOVA followed by Tukey post hoc test compared with pGL-3, respectively; ## P,0.01 for one-way ANOVA followed by Tukey post hoc test
compared with pPGC-100 bp.
doi:10.1371/journal.pone.0035823.g006
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of short-term memory to long-term memory. Ab altered
hippocampal-dependent synaptic plasticity and memory storage
and mediated synapse loss through the CREB signaling pathway,
which suggested a crucial role of CREB signaling in cognitive
dysfunction [34]. Therefore, further studies are needed to
demonstrate the exact role of CREB to the transcriptional activity
of PGC-1a and neuroprotective effects of DG.
Taken together, DG exerted neuroprotective effects against
Ab1–42-induced toxicity in vitro and in vivo. DG significantly
increased the viability of Ab1–42-treated neurons by inhibiting
oxidative stress and reversing mitochondrial dysfunction. Further-
more, PGC-1a upregulated by DG treatment might play an
important role against Ab1–42-induced neurotoxicity. Findings of
current study revealed new function and mechanism of DG on
neurotoxicity induced by Ab1–42, suggesting that DG may be
developed into a new drug for treatment of AD.
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